SeaCrest Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

SeaCrest Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,814	Closed	-$1.65M	–	651
2026 Q1	$1.65M	Buy	54,814 +949	+2%	+$30.5K	0.18%	103
2025 Q4	$1.75M	Buy	53,865 +7,680	+17%	+$189K	0.18%	102
2025 Q3	$933K	Buy	+46,185	New	+$811K	0.1%	188
2022 Q3	–	Sell	-2,093	Closed	-$16K	–	1430
2022 Q2	$16K	Buy	+2,093	New	+$18.2K	﹤0.01%	1577
2019 Q2	–	Sell	-7,218	Closed	-$113K	–	1706
2019 Q1	$113K	Sell	7,218 -5,150	-42%	-$90.8K	0.02%	650
2018 Q4	$191K	Sell	12,368 -23,280	-65%	-$477K	0.04%	431
2018 Q3	$768K	Buy	35,648 +725	+2%	+$16.8K	0.13%	159
2018 Q2	$849K	Buy	34,923 +17,205	+97%	+$351K	0.15%	133
2018 Q1	$303K	Buy	17,718 +600	+4%	+$11.7K	0.06%	365
2017 Q4	$324K	Buy	+17,118	New	+$258K	0.06%	349

Other funds holding TEVA

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

SeaCrest Wealth Management's TEVA Position: Q2 2026 in Review

SeaCrest Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 54,814 shares — an estimated $1.65M sold.

SeaCrest Wealth Management first reported a position in TEVA in Q4 2017 and held it in 10 quarters. The position peaked at $1.75M in Q4 2025. 99 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

SeaCrest Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SeaCrest Wealth Management sold 54,814 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
SeaCrest Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 10 quarters.
SeaCrest Wealth Management's Teva Pharmaceuticals position peaked at $1.75M in Q4 2025.
99 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.